Inactivity Behavior & Exercise Bariers in Patients With Behçet Disease

Status Recruiting

Clinical Trial Summary

Behçet's Disease (BD) is a chronic, inflammatory, rheumatic disease that is characterized by mucocutaneous lesions. Promoting physical activity level is one of the major goals in the management of patients with rheumatic diseases, it is important to determine the factors affecting physical activity level and exercise barriers. The aim of this study is to investigate physical activity level and exercise barriers in patients with BD. Physical activity level, exercise barriers, disease activity, fatigue, depression, pain, sleep disorders, aerobic capacity and quality of life will be assessed using International Physical Activity Questionnaire-Short Form (IPAQ),Exercise Benefits/Barriers Scale, Behçet Disease Current Activity Form (BDCAF), Fatigue Severity Scale (FSS), Beck Depression Inventory (BDI), McGill Pain Questionnaire- Short Form (MPQ-SF), Pittsburgh Sleep Quality Index, 6 minute walk test and Behçet's Disease Quality of Life Questionnaire, respectively.

Clinical Trial Description

Behçet's Disease (BD) is a chronic, inflammatory, rheumatic disease that is characterized by mucocutaneous lesions and can be seen major organ involvement such as eyes, musculoskeletal system, gastrointestinal system and central nervous system. Gender and clinical findings effect the prognosis of the disease. Physical activity is all body movements requiring energy expenditure over basal metabolism and contraction of skeletal muscle. Promoting physical activity level is one of the major goals in the management of patients with rheumatic diseases because of negative impact of sedentary lifestyle which depends on rheumatic involvement.Impaired quality of life, aerobic capacity, respiratory function and life satisfaction, sleep disorders, depression, anxiety and fatigue are seen commonly in BD patients like the other rheumatic diseases. Because of these symptoms, it is possible and expected that BD patients have low physical activity level. Considering that regular physical activity effects survival for patients and healthy people, it is important to determine the factors affecting physical activity level and exercise barriers. The aim of this study is to investigate physical activity level and exercise barriers in patients with BD. Physical activity level, exercise barriers, disease activity, fatigue, depression, pain, sleep disorders, aerobic capacity and quality of life will be assessed using International Physical Activity Questionnaire-Short Form (IPAQ),Exercise Benefits/Barriers Scale, Behçet Disease Current Activity Form (BDCAF), Fatigue Severity Scale (FSS), Beck Depression Inventory (BDI), McGill Pain Questionnaire- Short Form (MPQ-SF), Pittsburgh Sleep Quality Index, 6 minute walk test and Behçet's Disease Quality of Life Questionnaire, respectively. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03837236
Study type	Interventional
Source	Gazi University
Contact	Songul Baglan Yentur
Phone	+90 312 216 26 12
Email	songulbaglan23@hotmail.com
Status	Recruiting
Phase	N/A
Start date	February 8, 2019
Completion date	November 8, 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04528082` - Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease	Phase 3
Recruiting	`NCT04101604` - Biomarkers of Common Eye Diseases
Terminated	`NCT04609397` - A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease	Phase 2
Not yet recruiting	`NCT05128357` - IMPACT_BD (IMProving AdherenCe to Treatment in Behçet's Disease)
Not yet recruiting	`NCT04126850` - Pilot Project: The Amplicon and Metatranscriptomic Study of Intra and Extra Intestinal Microbiome in Non-infectious Uveitis Disease
Recruiting	`NCT05879419` - Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases	Phase 4
Completed	`NCT03209219` - Interferon α2a Versus Cyclosporine for Refractory Behçet's Disease Uveitis	Phase 3
Completed	`NCT04386824` - Erectile Dysfunction in Patients With Non Ocular Behçet's Disease
Completed	`NCT02648581` - Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease	Phase 2
Recruiting	`NCT04530461` - Serologic Profile of SARS CoV2 in COVID-19 Patients With Systemic Diseases
Recruiting	`NCT04334031` - Deployment o the Multidisciplinary Prospective Cohort Imminent	N/A
Not yet recruiting	`NCT04105439` - Plasma Soluble Urokinase Plasminogen Activator Receptor and Behçet's Disease .
Not yet recruiting	`NCT05715294` - The Effect of Music on Sleep Quality in Behçet's Patients	N/A
Active, not recruiting	`NCT06266247` - How Sirtuin Levels Change During Behçet Disease	N/A
Recruiting	`NCT04959435` - Understanding the Role of Oral Microbiota in Behçet's Disease (BEHCETBIOT)
Recruiting	`NCT03803462` - Behçet's Disease Overall Damage Index

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Inactivity Behavior and Exercise Bariers in Patients With Behçet Disease

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms